US FDA will publish a model OTC naloxone Drug Facts label “soon” to help switch sponsors developing labeling comprehension studies and final labeling, says Commissioner Scott Gottlieb.
The agency’s work on a Drug Facts label (DFL) for naloxone reflects its encouragement to drug companies to submit Rx-to-OTC switch applications for the ingredient, one part of the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?